BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36081393)

  • 21. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality.
    Saad F; Caliber M; Doros G; Haider KS; Haider A
    Aging Male; 2020 Mar; 23(1):81-92. PubMed ID: 30782054
    [No Abstract]   [Full Text] [Related]  

  • 22. Androgen replacement in men undergoing treatment for prostate cancer.
    Rhoden EL; Averbeck MA; Teloken PE
    J Sex Med; 2008 Sep; 5(9):2202-8. PubMed ID: 18638000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testosterone replacement therapy and the risk of prostate cancer.
    Warburton D; Hobaugh C; Wang G; Lin H; Wang R
    Asian J Androl; 2015; 17(6):878-81; discussion 880. PubMed ID: 25865848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Testosterone and prostate cancer: revisiting old paradigms.
    Isbarn H; Pinthus JH; Marks LS; Montorsi F; Morales A; Morgentaler A; Schulman C
    Eur Urol; 2009 Jul; 56(1):48-56. PubMed ID: 19375844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A rational approach to androgen therapy for hypogonadal men with prostate cancer.
    Kaufman J
    Int J Impot Res; 2006; 18(1):26-31. PubMed ID: 16208401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Testosterone Therapy Among Prostate Cancer Survivors.
    Nguyen TM; Pastuszak AW
    Sex Med Rev; 2016 Oct; 4(4):376-88. PubMed ID: 27474995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of the extent of therapy with prostate cancer in those receiving testosterone therapy in a US commercial insurance claims database.
    Lopez DS; Huang D; Tsilidis KK; Khera M; Williams SB; Urban RJ; Panagiotou OA; Kuo YF; Baillargeon J; Farias A; Krause T
    Clin Endocrinol (Oxf); 2019 Dec; 91(6):885-891. PubMed ID: 31498469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.
    Haider A; Zitzmann M; Doros G; Isbarn H; Hammerer P; Yassin A
    J Urol; 2015 Jan; 193(1):80-6. PubMed ID: 24980615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testosterone Therapy in Advanced Prostate Cancer.
    Chedrawe E; Sathe A; White J; Ory J; Ramasamy R
    Androg Clin Res Ther; 2022; 3(1):180-186. PubMed ID: 36684061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review.
    Shabsigh R; Crawford ED; Nehra A; Slawin KM
    Int J Impot Res; 2009; 21(1):9-23. PubMed ID: 18633357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular Morbidity and Mortality in Men - Findings From a Meta-analysis on the Time-related Measure of Risk of Exogenous Testosterone.
    Fallara G; Pozzi E; Belladelli F; Corsini C; Boeri L; Capogrosso P; Montorsi F; Salonia A
    J Sex Med; 2022 Aug; 19(8):1243-1254. PubMed ID: 35753891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular Disease, Hypogonadism and Erectile Dysfunction: Early Detection, Prevention and the Positive Effects of Long-Term Testosterone Treatment: Prospective Observational, Real-Life Data.
    Alwani M; Yassin A; Talib R; Al-Qudimat A; Aboumarzouk O; Al-Zoubi RM; Saad F; Haider KS; Al Ansari A
    Vasc Health Risk Manag; 2021; 17():497-508. PubMed ID: 34465997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Testosterone replacement therapy after primary treatment for prostate cancer.
    Agarwal PK; Oefelein MG
    J Urol; 2005 Feb; 173(2):533-6. PubMed ID: 15643240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.
    Kaufman JM; Graydon RJ
    J Urol; 2004 Sep; 172(3):920-2. PubMed ID: 15310998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer.
    Balbontin FG; Moreno SA; Bley E; Chacon R; Silva A; Morgentaler A
    BJU Int; 2014 Jul; 114(1):125-30. PubMed ID: 25101359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recurrence of prostate cancer in patients receiving testosterone supplementation for hypogonadism.
    Gray H; Seltzer J; Talbert RL
    Am J Health Syst Pharm; 2015 Apr; 72(7):536-41. PubMed ID: 25788507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current state of practice regarding testosterone supplementation therapy in men with prostate cancer.
    Kovac JR; Pan MM; Lipshultz LI; Lamb DJ
    Steroids; 2014 Nov; 89():27-32. PubMed ID: 25072793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefits and Health Implications of Testosterone Therapy in Men With Testosterone Deficiency.
    Traish AM
    Sex Med Rev; 2018 Jan; 6(1):86-105. PubMed ID: 29128268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testosterone therapy in the ageing male: what about the prostate?
    Schultheiss D; Machtens S; Jonas U
    Andrologia; 2004 Dec; 36(6):355-65. PubMed ID: 15541051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends.
    Kaplan AL; Trinh QD; Sun M; Carter SC; Nguyen PL; Shih YT; Marks LS; Hu JC
    J Sex Med; 2014 Apr; 11(4):1063-1070. PubMed ID: 24443943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.